Our Programs

The blood cancers we are fighting are:

Lymphoma, the most common blood cancer and the third most common cancer of childhood. The annual incidence of lymphomas has nearly doubled over the last three years. However, there have been rapid advances in the treatment of this disease and 80 percent of patients with Hodgkin's lymphoma can be cured.

Leukemia, a malignant cancer of the bone marrow and blood. Approximately 35,000 patients are diagnosed with leukemia annually. The relative adult five-year survival rate has more than tripled in the past 45 years, qualified by age, gender, race and type of leukemia. The leukemia death rate for children 0 to 14 years of age in the United States has declined 60 percent over the past three decades, due to modern treatment advances.

Myeloma, a disease of another blood cell, the plasma cell. Annually, approximately 16,000 new patients are diagnosed with myeloma. Overall survival in patients with myeloma has shown a modest improvement since the 1970s, however, the mortality rate for people of African descent is more than double the rate for Caucasians. Yale is a member of the Multiple Myeloma Consortium and is exploring novel treatment approaches to this cancer.

For more information about treating blood cancers, visit the Yale Cancer Center Hematology Program.

Other conditions we treat include disorders of:

  • Red blood cell production and coagulation
  • White blood cell production
  • Abnormal protein content in the blood
  • Genetic defects that causes abnormalities in hemoglobin
  • Hematologic disorders associated with other diseases